LGNYZ

Ligand Pharmaceuticals filed a DEFA14A (also structured as an 8-K) to report Amendment No. a minor…

This is a routine procedural filing with no standalone trading signal. Monitor for the definitive proxy statement from XOMA Royalty (expected within weeks) which will contain the actual vote…

Ligand Pharmaceuticals filed an 8-K reporting Amendment No. 1 to its Merger Agreement with XOMA…

This is a routine procedural amendment to add a holding company entity. No material change to the deal economics or timeline. Monitor for the definitive proxy statement from XOMA Royalty for…

Ligand Pharmaceuticals terminated its TR-Beta Program license with Viking Therapeutics, alleging…

The legal dispute over termination rights creates binary risk: if Ligand prevails, it recovers program rights but faces development costs; if Viking prevails, Ligand loses all future economics from…

Ligand Pharmaceuticals (LGND) is acquiring XOMA Royalty Corporation in a cash deal worth $39.00…

Monitor the shareholder vote and regulatory approvals, as the deal's accretive nature and portfolio expansion make it a significant positive catalyst for Ligand; watch for integration updates and…